AbSci
AbSci is an e. Coli expression system for protein production founded in 2011 by Sean McClain.
10
Funding Rounds
$437.9m
Money raised
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
| Name | Phone | Social networks | |
|---|---|---|---|
| Se** Mc***** |
|
- |
Funding
Funding series
Funding Series Analysis
The company AbSci has raised a total of $215.4m in funding over 10 rounds.
Key Insights:
- AbSci Initial public offering (IPO): $200m
- AbSci Series D round, January 2020: $15.4m
- AbSci Corp funding round, October 2020: $65m
- AbSci Venture round, March 2021: $125m
- AbSci Venture round, December 2019: $5m
- AbSci Series D round, January 2019: $10.4m
- AbSci Series A round, February 2016: $5.1m
- AbSci Series C round, May 2018: $12m
Industries
AbSci is active in the following industries: